Zhitong Finance App News, Shiyao Innovation (300765.SZ) announced that the company's holding subsidiary, Shiyao Group Jushi Biopharmaceutical Co., Ltd. (hereinafter referred to as “Jushi Biotech”), recently received the “Drug Clinical Trial Approval Notice” for SYS6062 approved and issued by the China Drug Administration (hereinafter referred to as the “State Drug Administration”) and will conduct clinical trials in the near future.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.